Goldfarb DS - Search Results

1

l-Cystine Diamides as l-Cystine Crystallization Inhibitors for Cystinuria.

Hu L, Yang Y, Aloysius H, Albanyan H, Yang M, Liang JJ, Yu A, Shtukenberg A, Poloni LN, Kholodovych V, Tischfield JA, Goldfarb DS, Ward MD, Sahota A. Hu L, et al. Among authors: goldfarb ds. J Med Chem. 2016 Aug 11;59(15):7293-8. doi: 10.1021/acs.jmedchem.6b00647. Epub 2016 Jul 26. J Med Chem. 2016. PMID: 27409142 Free PMC article.

2

Cystinuria.

Mattoo A, Goldfarb DS. Mattoo A, et al. Among authors: goldfarb ds. Semin Nephrol. 2008 Mar;28(2):181-91. doi: 10.1016/j.semnephrol.2008.01.011. Semin Nephrol. 2008. PMID: 18359399 Review.

3

Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design.

Rimer JD, An Z, Zhu Z, Lee MH, Goldfarb DS, Wesson JA, Ward MD. Rimer JD, et al. Among authors: goldfarb ds. Science. 2010 Oct 15;330(6002):337-341. doi: 10.1126/science.1191968. Science. 2010. PMID: 20947757 Free PMC article.

4

Novel cystine ester mimics for the treatment of cystinuria-induced urolithiasis in a knockout mouse model.

Sahota A, Parihar JS, Capaccione KM, Yang M, Noll K, Gordon D, Reimer D, Yang I, Buckley BT, Polunas M, Reuhl KR, Lewis MR, Ward MD, Goldfarb DS, Tischfield JA. Sahota A, et al. Among authors: goldfarb ds. Urology. 2014 Nov;84(5):1249.e9-15. doi: 10.1016/j.urology.2014.07.043. Epub 2014 Oct 24. Urology. 2014. PMID: 25443947 Free PMC article.

5

Cystine growth inhibition through molecular mimicry: a new paradigm for the prevention of crystal diseases.

Lee MH, Sahota A, Ward MD, Goldfarb DS. Lee MH, et al. Among authors: goldfarb ds. Curr Rheumatol Rep. 2015 May;17(5):33. doi: 10.1007/s11926-015-0510-7. Curr Rheumatol Rep. 2015. PMID: 25874348 Free PMC article. Review.

6

Cystinuria: genetic aspects, mouse models, and a new approach to therapy.

Sahota A, Tischfield JA, Goldfarb DS, Ward MD, Hu L. Sahota A, et al. Among authors: goldfarb ds. Urolithiasis. 2019 Feb;47(1):57-66. doi: 10.1007/s00240-018-1101-7. Epub 2018 Dec 4. Urolithiasis. 2019. PMID: 30515543 Free PMC article. Review.

7

Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria.

Malieckal DA, Modersitzki F, Mara K, Enders FT, Asplin JR, Goldfarb DS. Malieckal DA, et al. Among authors: goldfarb ds. Urolithiasis. 2019 Dec;47(6):549-555. doi: 10.1007/s00240-019-01128-y. Epub 2019 Apr 13. Urolithiasis. 2019. PMID: 30980122 Free PMC article. Clinical Trial.

8

Urinary cystine excretion and capacity in patients with cystinuria.

Goldfarb DS, Coe FL, Asplin JR. Goldfarb DS, et al. Kidney Int. 2006 Mar;69(6):1041-7. doi: 10.1038/sj.ki.5000104. Kidney Int. 2006. PMID: 16501494 Free article.

9

Update on cystinuria.

Sumorok N, Goldfarb DS. Sumorok N, et al. Among authors: goldfarb ds. Curr Opin Nephrol Hypertens. 2013 Jul;22(4):427-31. doi: 10.1097/MNH.0b013e3283621c5d. Curr Opin Nephrol Hypertens. 2013. PMID: 23666417 Free PMC article. Review.

10

Health-related quality of life (HRQoL) in cystine compared with non-cystine stone formers.

Modersitzki F, Pizzi L, Grasso M, Goldfarb DS. Modersitzki F, et al. Among authors: goldfarb ds. Urolithiasis. 2014 Feb;42(1):53-60. doi: 10.1007/s00240-013-0621-4. Epub 2013 Nov 20. Urolithiasis. 2014. PMID: 24253538 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

326 results

Search Page